Skip to content

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy on Stage IVB Ovarian Cancer With Supradiaphragmatic Lymph Node Metastasis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05005650
Acronym
SDLNOC
Enrollment
121
Registered
2021-08-13
Start date
2021-06-01
Completion date
2021-12-31
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Metastases, Ovarian Cancer Stage IV

Keywords

internal mammary lymph node, supraclavicular lymph node, cardiophrenic lymph node

Brief summary

To evaluate the survival impact of extensive lymphadenectomy as part of debulking surgery in stage IVB ovarian cancer with supradiaphragmatic lymph node metastasis.

Interventions

debulking surgery as primary debulking surgery or interval debulking surgery

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Histologically diagnosed ovarian, fallopian tubal, primary peritoneal cancer * Patients suspected of metastatic lymph nodes in the cardiophrenic, internal mammary, and/or supraclavicular lymph node by CT (size larger than 5mm) * Patients clinically diagnosed FIGO stage IVB ovarian, fallopian tubal, primary peritoneal cancer * Patients underwent debulking surgery (primary debulking surgery or interval debulking surgery) at Seoul National University Hospital from January 2010 to January 2020 * Patients age 18-90

Exclusion criteria

* Borderline or benign ovarian disease * Patient didn't undergo debulking surgery * Non-epithelial ovarian cancer

Design outcomes

Primary

MeasureTime frameDescription
Progression-free survivalFrom date of treatment until the date of first documented progression or date of death (by any cause, in the absence of disease progression) whichever came first, assessed up to 120 monthsthe time interval from the treatment start date to disease recurrence or progression date

Secondary

MeasureTime frameDescription
Overall survivalFrom the date of treatment start date until death due to any cause, assessed up to 120 monthsthe time interval from the treatment start date to death or end of study date

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026